Syros Pharmaceuticals (SYRS) Preclinical data on SY-1425 Presented at ASH
Tweet Send to a Friend
Syros Pharmaceuticals (NASDAQ: SYRS) today announced that new preclinical data on SY-1425, its first-in-class selective retinoic acid receptor alpha (RARĪ±) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
